A Phase II Trial of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 25 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2016 New trial record